Drug Trial News

RSS

Trial shows potential benefit of ketogenic diet for treating psychotic disorders

Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders.

8 Jul 2026

Novel leukemia therapy successfully eradicates measurable residual disease

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

7 Jul 2026

Targeted therapy shows promise against KRAS-driven metastatic pancreatic cancer

An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented today at the ESMO Gastrointestinal Cancers Congress 2026.

3 Jul 2026

WHO launches PARTNERS clinical trial for Bundibugyo virus treatments

In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the PARTNERS clinical trial has opened enrolment today for patients in the Democratic Republic of the Congo.

3 Jul 2026

Move to quit: Exercise boosts smoking quit rates

A pack-a-day smoker can spend around $14,000 a year on cigarettes, yet despite the financial and health costs, quitting remains one of the most difficult changes many people will ever attempt.

3 Jul 2026

Low-cost B-cell depleting therapy is as effective as standard treatment for multiple sclerosis

A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a low-cost B-cell depleting therapy, is as effective as ocrelizumab in newly diagnosed relapsing multiple sclerosis (MS).

2 Jul 2026

Targeted therapy doubles progression-free survival in rare bile duct cancer

Results of the ongoing eNRGy trial, a single-arm, multicenter, global phase 2 clinical trial evaluating zenocutuzumab in solid tumors positive for Neuregulin 1 (NRG1) gene fusions, reported manageable side effects and clinically meaningful efficacy – including a near doubling of progression-free survival compared to expectations with standard of care – in previously treated patients with advanced NRG1-positive cholangiocarcinoma.

2 Jul 2026

New national program targeting harmful and unnecessary medicine use in Australia

...

1 Jul 2026

Trial evaluates interdisciplinary care for veterans with brain trauma and PTSD

The Medical College of Wisconsin (MCW) is leading a new multi-center clinical trial to evaluate an interdisciplinary rehabilitation model for military veterans and first responders with mild traumatic brain injury (mTBI) and co-occurring disorders such as depression, anxiety, and post-traumatic stress disorder (PTSD).

30 Jun 2026

New trial shows oral therapy increases growth in children with achondroplasia

New findings from a trial conducted at Children's Hospital Colorado (Children's Colorado) and University of Colorado (CU) Anschutz School of Medicine demonstrate significantly increased growth rates in children with achondroplasia, the most common form of dwarfism.

30 Jun 2026

First-in-human trial tests safer T-cell therapy for pediatric brain cancers

Researchers report encouraging early results from a first-in-human clinical trial led by Children's National using a new T-cell immunotherapy for children and young adults with some of the deadliest brain tumors, including diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system (CNS) tumors.

30 Jun 2026

Common drug shows promise in preventing post-surgical liver failure

A multi-center study, co-led by researchers at Mayo Clinic and Michigan State University, found that patients who received tranexamic acid during liver surgery were three times less likely to develop post-hepatectomy liver failure than patients who received a placebo.

25 Jun 2026

FDA approves palbociclib combination for advanced HR-positive HER2-positive breast cancer

Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for adult patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) locally advanced or metastatic breast cancer following induction treatment.

24 Jun 2026

New oral drug shows promise for chronic heart failure treatment

An early clinical study shows that a new oral drug is safe and well-tolerated in patients with chronic heart failure.

24 Jun 2026

UCI Health launches world's first embryonic stem cell trial for Huntington's disease

UCI Health, the clinical enterprise of the University of California, Irvine, has opened the world's first in-human embryonic stem cell-derived clinical trial for Huntington's disease.

23 Jun 2026

New drug could double survival time in patients with advanced pancreatic cancer

A new medication could double survival time in patients with advanced pancreatic cancer, according to Phase III clinical trial results presented at the American Society of Clinical Oncology (ASCO) 2026 annual meeting and simultaneously published in The New England Journal of Medicine.

22 Jun 2026

Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802

Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PTD802, the Company's lead therapeutic candidate.

From Pheno Therapeutics 22 Jun 2026

First human trial targets aging immune cells for healthier immunity

A first-in-human clinical trial of an immune rejuvenation therapy designed to restore the function of worn-out T cells is expected to begin later this year, building on research led by UCL scientists into the mechanisms of immune aging.

17 Jun 2026

AI-designed drug for Parkinson's begins first human trial

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969.

17 Jun 2026

Novel gene therapy appears to be safe for Friedreich ataxia cardiomyopathy

A new gene therapy appears to be safe in patients diagnosed with Friedreich ataxia cardiomyopathy, a progressive and fatal inherited cardiac disease, according to a phase 1 clinical trial led by Weill Cornell Medicine researchers.

17 Jun 2026